Synaptogenix (Synaptogenix) Debt-to-Equity : 0.00 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Synaptogenix Debt-to-Equity?

Synaptogenix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Synaptogenix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Synaptogenix's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $22.88 Mil. Synaptogenix's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Synaptogenix's Debt-to-Equity or its related term are showing as below:

SNPX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08 Med: 0.08 Max: 0.08
Current: 0.1

During the past 5 years, the highest Debt-to-Equity Ratio of Synaptogenix was 0.08. The lowest was 0.08. And the median was 0.08.

SNPX's Debt-to-Equity is ranked better than
58.61% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs SNPX: 0.10

Synaptogenix Debt-to-Equity Historical Data

The historical data trend for Synaptogenix's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Synaptogenix Debt-to-Equity Chart

Synaptogenix Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Synaptogenix Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial														-	0.08	-	-	-

Competitive Comparison of Synaptogenix's Debt-to-Equity

For the Biotechnology subindustry, Synaptogenix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Synaptogenix's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Synaptogenix's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Synaptogenix's Debt-to-Equity falls into.

Synaptogenix Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Synaptogenix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	25.584
	=	0.00

Synaptogenix's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	22.877
	=	0.00

Synaptogenix (NAS:SNPX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Synaptogenix Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Synaptogenix's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Synaptogenix (Synaptogenix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Synaptogenix Inc (NAS:SNPX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036

Website

https://www.synaptogen.com

Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.

Executives

Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Robert Weinstein	officer: Chief Financial Officer	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Bruce Bernstein	director	780 THIRD AVENUE, 12TH FLOOR, NEW YORK NY 10017
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
William S. Singer	director	C/O KIRKLAND & ELLIS LLP, 300 NORTH LASALLE, CHICAGO IL 60654
Daniel L. Alkon	director, officer: Chief Scientific Officer	C/O NEUROTROPE, INE., 205 EAST 42ND STREET - 20TH FLOOR, NEW YORK NY 10017
Alan J Tuchman	director, officer: Chief Executive Officer	18 SYCAMORE ROAD, MAHOPAC NY 10541
George Perry	director	C/O NEUROTROPE, INC., 205 EAST 42ND STREET, 17TH FLOOR, NEW YORK NY 10010